REGISTRY OF TREATMENT PATTERNS IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) WITH PROGRESSION DURING OR AFTER DOCETAXEL-BASED REGIME

Not Applicable

• Conditions: metastatic castration registant prostate cancer

• Registration Number: JPRN-UMIN000007729
• Lead Sponsor: SaKK

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-04-12
• Study Completion: 2015-07-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Male
• Target Recruitment: 900

Inclusion Criteria

Not provided

Exclusion Criteria

-Patients having already started a new treatment line for mCRPC -Participation in a clinical study in which study treatment is blinded

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sequence of treatment lines observed during a period of 12 months in patients who received docetaxel-based regimen and have disease progression

Secondary Outcome Measures

Name	Time	Method
-Physician criteria for therapeutic decision -Characteristics of patients who receive a further treatment after docetaxel-based regimen -Tumor response during docetaxel-based regimen -Tumor reponse for subsequent treatments -Type of disease progression during docetaxel based-regimen -Type of disease progression during subsequent lines of treatment -Sequence of treatments other than chemotherapy and hormonotherapy -Progression-free survival and overall survival with different treatment modalities -QOL ( EQ-5D; FACT-P)